{
  "ticker": "KYMR",
  "company_name": "Kymera Therapeutics",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06028230",
      "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Hidradenitis Suppurativa",
      "start_date": "2023-09-29",
      "completion_date": "2025-11-12",
      "enrollment": 0,
      "sponsor": "Sanofi"
    },
    {
      "nct_id": "NCT06945458",
      "title": "Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Atopic Dermatitis",
      "start_date": "2025-04-17",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06058156",
      "title": "Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2023-11-09",
      "completion_date": "2025-11-20",
      "enrollment": 0,
      "sponsor": "Sanofi"
    },
    {
      "nct_id": "NCT05233033",
      "title": "Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation",
      "start_date": "2022-06-13",
      "completion_date": "2023-07-28",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04440410",
      "title": "Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Hidradenitis Suppurativa, Dermatitis, Atopic",
      "start_date": "2020-05-28",
      "completion_date": "2021-03-24",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07323654",
      "title": "A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Eosinophilic Asthma",
      "start_date": "2026-03",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06673667",
      "title": "First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants Study",
      "start_date": "2024-10-22",
      "completion_date": "2025-04-23",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05775406",
      "title": "Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors",
      "start_date": "2023-05-15",
      "completion_date": "2024-12-18",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07217015",
      "title": "A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2025-11-24",
      "completion_date": "2028-06",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05225584",
      "title": "Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors",
      "start_date": "2022-05-19",
      "completion_date": "2025-03-03",
      "enrollment": 0,
      "sponsor": "Kymera Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 11,
    "by_phase": {
      "PHASE2": 4,
      "PHASE1": 6,
      "": 1
    },
    "by_status": {
      "TERMINATED": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "COMPLETED": 6,
      "RECRUITING": 2
    },
    "active_trials": 3,
    "completed_trials": 6,
    "conditions": [
      "Atopic Dermatitis",
      "Eosinophilic Asthma",
      "Healthy Participants Study",
      "Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa",
      "Hidradenitis Suppurativa",
      "Hidradenitis Suppurativa, Dermatitis, Atopic",
      "Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors",
      "Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors",
      "Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:02:58.824680",
    "search_query": "Kymera Therapeutics",
    "url": "https://clinicaltrials.gov/search?term=Kymera+Therapeutics"
  }
}